Circulating Biomarkers World Congress, March 23-24, 2015, Boston: Exosomes, Microvesicles, Circulating DNA, Circulating RNA, Circulating Tumor Cells, Sample Preparation

Reporter: Aviva Lev-Ari, PhD, RN

 

 

VENUE

Wyndham Boston Beacon Hill
5 Blossom Street,
Boston, Massachusetts, 02114
USA

The Conference Presentations, Exhibition, as well as Lunches and Networking Reception will be held on the 15th. Floor of the Hotel featuring stunning views of the Charles River, Boston, and MIT.

The Wyndham Boston Beacon Hill is on Blossom Street which is right off Cambridge Street.  A 5-minute walk from the MBTA “T” Red Line Charles/MGH Stop.

Also, the Wyndham Boston Beacon Hill is right across from the Massachusetts General Hospital (MGH).

The 2^nd. Annual SELECTBIO Circulating Biomarkers World Congress 2015 brings together academic researchers as well as industry participants to present and discuss the most up-to-date research and commercial activities in the translation of various circulating biomarker classes towards the clinic.

This Congress discusses Nucleic Acid-based Biomarkers, Protein-based Biomarkers, Extracellular Vesicle (EV)-based Biomarkers (contained within exosomes and microvesicles), and Circulating Tumor Cell (CTC)-based Biomarkers.

One of the conference tracks focuses on Sample Preparation, a key component of the workflow in circulating biomarker isolation for research, and deployment in the clinic.

A co-located exhibit hall features companies developing technologies and products for the complete workflow from sample isolation, preparation, through data analysis.

Conference delegates receive access to all three co-located conference tracks, can mix-and-match presentations from all three tracks thereby maximizing the conference experience, and can network with delegates from the various co-located tracks and exhibition.

All conference attendees receive a USB drive loaded with the most up-to-date publications and reviews focused on various classes of circulating biomarkers, these offer valuable information for R&D presentations and business plans.

Present Your Research in a Poster at this Conference. Poster Submission Deadline:  March 16, 2015

http://selectbiosciences.com/conferences/index.aspx?conf=CBWC2015

Select Biosciences is organizing a 3-track event entitled Circulating Biomarkers World Congress 2015, Boston, March 23-24, 2015 bringing together all the relevant topics and speakers from around the world addressing comprehensively the Circulating Biomarkers field.

Co-Located Parallel Congress Tracks 

1.

Exosomes and Microvesicles

2.

Circulating DNA, Circulating RNA, Circulating Tumor Cells

3.

Sample Preparation and Analysis

Topics Covered in this Congress

•

Biofluid Biopsy Development and Various Biomarker Classes

•

Circulating DNA and RNA as Potential Biomarker Classes

•

Circulating Tumor Cells (CTCs): Methodologies for Isolation and Interrogation

•

Circulating Tumor DNA (ctDNA): Potential for Monitoring Disease Progression in Oncology and for Correctly Deploying Targeted Therapeutics and Enabling Personalized Medicine

•

Digital PCR Applications for Circulating Biomarker Interrogation

•

EV Cargo and Biomarker Potential–Classes of Biomarker Cargo: DNA, RNA, Protein

•

EVs as Delivery Vehicles–Potential of EVs Beyond Biomarkers to Engineered Delivery Vectors

•

Exosomes and Microvesicles in Various Disease Classes (Cancer, Cardiovascular Disease, CNS)

•

Exosomes, Microvesicles, and Other Classes of Extracellular Vesicles (EVs) as Circulating Biomarkers

•

Head-to-Head Comparison of CTCs with ctDNA as Circulating Biomarkers

•

Mass Spectrometry for Protein Biomarker Analysis

•

Methodologies for Isolating and Characterizing Extracellular Nucleic Acids (cfDNA, Extracellular RNA)

•

Microfluidics/Lab-on-a-Chip Methodologies for Sample Preparation

•

Next Generation Sequencing (NGS) for Characterizing Circulating Biomarkers: Applications of RNA-Seq for Studying Exosomes and Microvesicles

•

Sample Preparation Technologies for Circulating Biomarkers in the Point-of-Care (POC) Diagnostics Environment

•

Tools and Technologies for Monitoring Extracellular Nucleic Acids in Biological Fluids

Confirmed Keynote Speakers

•

David Wong, Felix & Mildred Yip Professor, Associate Dean of Research, Director UCLA Center for Oral/Head & Neck Oncology Research. Saliva-based Exosomes for Liquid Biopsies

•

Dominique de Kleijn, Professor, National University of Singapore. Extracellular Vesicles as Biomarkers for Cardiovascular Disease

•

Doug Taylor, Chief Scientific Officer, Exosome Sciences. Exosomes: From “Dust” to Multiplexed Diagnostic Biomarker

•

Frank Slack, Professor of Medicine & Pathology, Director, Institute of RNA Medicine, Beth Israel Deaconess Medical Center/Harvard Medical School. MicroRNA Biomarkers of Disease

•

Deaconess Medical Center/Harvard Medical School. MicroRNA Biomarkers of Disease

•

Jamie Platt, Vice President, Genomic Solutions, Geneuity (Molecular Pathology Laboratory Network, Inc.). Getting Back to Basics: Sample Preparation Considerations for Advanced Sequencing Technologies

•

Johan Skog, Chief Scientific Officer, Exosome Diagnostics Exosome Biomarkers: Current State and Future Directions

•

John Palma, Director, Medical & Scientific Affairs, Roche Molecular Systems. Blood-based Detection of EGFR Mutations is Predictive of Survival Outcomes in Patients Treated with First-line Erlotinib Intercalated with Chemotherapy

•

Lance Liotta, Professor, George Mason University. Nanotrap Nanoparticles for Discovery and Measurement of Previously Invisible Low Abundance Biomarkers

•

Mark Sausen, Director, Research & Development, Personal Genome Diagnostics. Detection and Genotyping of Sequence and Structural Alterations in the Circulation of Cancer Patients

•

Nitzan Rosenfeld, Senior Group Leader, Cancer Research UK, University of Cambridge Noninvasive Cancer Genomics and Exploring Potential Clinical Applications of Circulating Tumor DNA

•

Phil Stephens, Chief Scientific Officer, Foundation Medicine. Assessing the Promise of Liquid Biopsy to Enable Detection of Druggable Genomic Alterations Using Targeted NGS Assays Optimized for CTCs and ctDNA

•

Vincent Miller, Chief Medical Officer, Foundation Medicine Comprehensive Genomic Profiling in Clinical Oncology: Overcoming the Challenges

•

Xandra Breakefield, Professor/Geneticist, MGH-Harvard Medical School. Extracellular RNA in Biofluids as Biomarkers of Disease

•

Yoshiya Oda, President, Eisai. Circulating Biomarkers for Oncology/Alzheimer’s Disease Drug Development

Confirmed Speakers Include

•

Abhijit Patel, Assistant Professor, Yale University School of Medicine

•

Anastasia Khvorova, Professor, RNA Therapeutics Institute, University of Massachusetts Medical School

•

Brian Dougherty, Translational Genomics Lead, AstraZeneca Oncology

•

Casey Maguire, Assistant Professor of Neurology, Massachusetts General Hospital/Harvard Medical School

•

Cesar Castro, Director – Cancer Program, Center for Systems Biology, Massachusetts General Hospital/Harvard Medical School

•

Cicek Gercel-Taylor, Clinical Research Director, Exosome Sciences

•

Daniel Irimia, Assistant Professor, Division of Surgery, Science & Bioengineering, Massachusetts General Hospital/Harvard Medical School

•

Daniel Jay, Professor, Tufts University

•

Davina Gale, Co-Founder & Head of Molecular Diagnostics, Inivata

•

Dolores Di Vizio, Professor, Cedars-Sinai Los Angeles

•

Elena Aikawa, Associate Professor of Medicine, Brigham and Women’s Hospital, Harvard Medical School

•

Farideh Bischoff, Executive Director, Silicon Biosystems

•

Hakho Lee, Assistant Professor, Massachusetts General Hospital

•

Héctor Peinado Selgas, Assistant Professor of Molecular Biology, Weill Medical College of Cornell University

•

Hugh Fan, Professor, University of Florida

•

Joshua Levin, Senior Scientist/Group Leader, The Broad Institute of MIT and Harvard

•

Katherine Richardson, Vice President, Research & Development, Transgenomic

•

Kelli Bramlett, Senior Manager, Research & Development, Thermo Fisher Scientific

•

Kendall Keuren-Jensen, Associate Professor, Translational Genomics Research Institute (TGEN)

•

Kenneth Kotz, Massachusetts General Hospital

•

Kristin Ciriello Pothier, Partner & Managing Director, Life Sciences Leader, Ernst and Young LLP

•

Leileata Russo, Research Professor, Massachusetts General Hospital (MGH)

•

Leonora Balaj, Research Fellow, Massachusetts General Hospital

•

Lidong Qin, Associate Professor, CPRIT Scholar, Houston Methodist Research Institute

•

Mark Reed, Professor of Electrical Engineering and Applied Physics, Yale University

•

Martin Beaulieu, Director, Regulus Therapeutics

•

Mike Makrigiorgos, Professor of Radiation Oncology, Dana Farber Cancer Institute/Harvard Medical School

•

Pavan Kumar, Senior Scientist, Eisai

•

Roopali Gandhi, Assistant Professor in Neurology, Head of MS Biomarkers, Brigham and Women’s Hospital/Harvard Medical School

•

Sandra Gaston, Director, Tufts Medical Center

•

Saumya Das, Assistant Professor in Medicine, Harvard Medical School

•

Tony Godfrey, Associate Chair – Research, Department of Surgery, Boston University Medical Center

•

Veronique Neumeister, Laboratory Director of Specialized Translational Services, Yale University

•

Weian Zhao, Assistant Professor, University of California-Irvine

•

Yaoyu Wang, Associate Director, Center for Cancer Computational Biology, Dana-Farber Cancer Institute

•

Yong Zeng, Assistant Professor, University of Kansas